• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Processing sites are different in the generation of HLA-A2.1-restricted, T cell reactive tumor antigen epitopes and viral epitopes.加工位点在HLA - A2.1限制性、T细胞反应性肿瘤抗原表位和病毒表位的产生过程中有所不同。
Int J Immunopathol Pharmacol. 2006 Oct-Dec;19(4):853-70. doi: 10.1177/039463200601900415.
2
Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2.来自肿瘤相关抗原酪氨酸酶相关蛋白-2的天然加工和隐蔽的HLA-A2.1限制性表位
Int J Cancer. 2000 Jul 15;87(2):241-6.
3
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.针对前列腺酸性磷酸酶的 HLA-A2 限制性 T 细胞表位。
Cancer Immunol Immunother. 2010 Jun;59(6):943-53. doi: 10.1007/s00262-010-0820-6. Epub 2010 Feb 6.
4
Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.针对癌症睾丸抗原 SSX-2 的疫苗可引发 HLA-A2 表位特异性细胞毒性 T 细胞。
J Immunother. 2011 Oct;34(8):569-80. doi: 10.1097/CJI.0b013e31822b5b1d.
5
Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice.鉴定人 MHC-I HPV18 E6/E7 特异性 CD8+T 细胞表位,并在 HLA-A2 转基因小鼠中生成 HPV18 E6/E7 表达的腺鳞癌。
J Biomed Sci. 2022 Oct 12;29(1):80. doi: 10.1186/s12929-022-00864-5.
6
Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.在黑素小体蛋白上鉴定由HLA - A1、- A2和- A3等位基因限制的肿瘤浸润性T淋巴细胞所识别的新黑色素瘤表位。
J Immunol. 1998 Dec 15;161(12):6985-92.
7
Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.DNA疫苗在HLA - A2转基因小鼠中诱导的HLA - A2限制性HPV - 16 E7特异性CD8(+) T细胞免疫反应的特征分析
Gene Ther. 2006 Jan;13(1):67-77. doi: 10.1038/sj.gt.3302607.
8
[Prediction synthesis and identification of HLA-A2-restricted cytotoxic T lymphocyte epitopes of the tumor antigen MAGE-n].[肿瘤抗原MAGE-n的HLA - A2限制性细胞毒性T淋巴细胞表位的预测合成与鉴定]
Zhonghua Yi Xue Za Zhi. 2003 Jun 25;83(12):1080-3.
9
Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.表达靶向HLA - A201或完整MART - 1/黑色素瘤抗原A的非复制重组痘苗病毒的免疫原性。
Cancer Gene Ther. 2001 Sep;8(9):655-61. doi: 10.1038/sj.cgt.7700351.
10
Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.新型人类癌症抗原POTE中HLA - A2.1限制性CTL表位的鉴定与增强
PLoS One. 2013 Jun 4;8(6):e64365. doi: 10.1371/journal.pone.0064365. Print 2013.

引用本文的文献

1
Immune Checkpoints Are New Therapeutic Targets in Regulating Cardio-, and Cerebro-Vascular Diseases and CD4Foxp3 Regulatory T Cell Immunosuppression.免疫检查点是调节心脑血管疾病和CD4Foxp3调节性T细胞免疫抑制的新治疗靶点。
Int J Drug Discov Pharm. 2024 Dec;3(4). doi: 10.53941/ijddp.2024.100022. Epub 2024 Nov 26.
2
Vascular Endothelial Cells and Innate Immunity.血管内皮细胞与先天免疫
Arterioscler Thromb Vasc Biol. 2020 Jun;40(6):e138-e152. doi: 10.1161/ATVBAHA.120.314330. Epub 2020 May 27.
3
Co-signaling receptors regulate T-cell plasticity and immune tolerance.共刺激信号受体调节 T 细胞可塑性和免疫耐受。
Front Biosci (Landmark Ed). 2019 Jan 1;24(1):96-132. doi: 10.2741/4710.
4
DNA Checkpoint and Repair Factors Are Nuclear Sensors for Intracellular Organelle Stresses-Inflammations and Cancers Can Have High Genomic Risks.DNA 检查点与修复因子是细胞内细胞器应激的核传感器——炎症和癌症可能具有高基因组风险。
Front Physiol. 2018 May 11;9:516. doi: 10.3389/fphys.2018.00516. eCollection 2018.
5
Lysophospholipids induce innate immune transdifferentiation of endothelial cells, resulting in prolonged endothelial activation.溶血磷脂诱导内皮细胞先天免疫转分化,导致内皮细胞持续激活。
J Biol Chem. 2018 Jul 13;293(28):11033-11045. doi: 10.1074/jbc.RA118.002752. Epub 2018 May 16.
6
GATA3, HDAC6, and BCL6 Regulate FOXP3+ Treg Plasticity and Determine Treg Conversion into Either Novel Antigen-Presenting Cell-Like Treg or Th1-Treg.GATA3、HDAC6 和 BCL6 调节 FOXP3+Treg 的可塑性,并决定 Treg 是转化为新型抗原呈递细胞样 Treg 还是 Th1-Treg。
Front Immunol. 2018 Jan 26;9:45. doi: 10.3389/fimmu.2018.00045. eCollection 2018.
7
A comprehensive data mining study shows that most nuclear receptors act as newly proposed homeostasis-associated molecular pattern receptors.一项全面的数据挖掘研究表明,大多数核受体作为新提出的与内稳态相关的分子模式受体发挥作用。
J Hematol Oncol. 2017 Oct 24;10(1):168. doi: 10.1186/s13045-017-0526-8.
8
Metabolic Diseases Downregulate the Majority of Histone Modification Enzymes, Making a Few Upregulated Enzymes Novel Therapeutic Targets--"Sand Out and Gold Stays".代谢性疾病下调大多数组蛋白修饰酶,使少数上调的酶成为新型治疗靶点——“沙汰金存” 。
J Cardiovasc Transl Res. 2016 Feb;9(1):49-66. doi: 10.1007/s12265-015-9664-y. Epub 2016 Jan 8.
9
Analysis for Carom complex, signaling and function by database mining.通过数据库挖掘分析钙黏蛋白复合物、信号转导及功能。
Front Biosci (Landmark Ed). 2016 Jan 1;21(4):856-72. doi: 10.2741/4424.
10
The Role of Immunogenicity in Cardiovascular Disease.免疫原性在心血管疾病中的作用。
World Heart J. 2011 Jan 1;3(1):1-29.

本文引用的文献

1
Vaccines for tumour prevention.用于肿瘤预防的疫苗。
Nat Rev Cancer. 2006 Mar;6(3):204-16. doi: 10.1038/nrc1815.
2
New concepts in tumor antigens: their significance in future immunotherapies for tumors.肿瘤抗原的新概念:它们在未来肿瘤免疫治疗中的意义。
Cell Mol Immunol. 2005 Oct;2(5):331-41.
3
Processing and presentation of tumor antigens and vaccination strategies.肿瘤抗原的处理与呈递及疫苗接种策略
Curr Opin Immunol. 2006 Feb;18(1):98-104. doi: 10.1016/j.coi.2005.11.013. Epub 2005 Dec 15.
4
Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding.通过整合蛋白酶体切割、TAP转运和MHC I类结合的预测来模拟MHC I类途径。
Cell Mol Life Sci. 2005 May;62(9):1025-37. doi: 10.1007/s00018-005-4528-2.
5
Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.癌症免疫治疗中诱导CD4+ T细胞应答的遗传方法。
J Gene Med. 2005 Jun;7(6):686-95. doi: 10.1002/jgm.713.
6
Proteasome inhibition as a novel therapeutic target in human cancer.蛋白酶体抑制作为人类癌症的一种新型治疗靶点。
J Clin Oncol. 2005 Jan 20;23(3):630-9. doi: 10.1200/JCO.2005.11.030.
7
Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes.自身抗原转录本非经典剪接增加为未耐受表位的表达提供了结构基础。
J Allergy Clin Immunol. 2004 Dec;114(6):1463-70. doi: 10.1016/j.jaci.2004.09.006.
8
Induction and regulation of IFNs during viral infections.病毒感染期间干扰素的诱导与调节。
J Interferon Cytokine Res. 2004 Aug;24(8):439-54. doi: 10.1089/1079990041689665.
9
A listing of human tumor antigens recognized by T cells: March 2004 update.T细胞识别的人类肿瘤抗原列表:2004年3月更新
Cancer Immunol Immunother. 2005 Mar;54(3):187-207. doi: 10.1007/s00262-004-0560-6. Epub 2004 Aug 7.
10
Post-proteasomal antigen processing for major histocompatibility complex class I presentation.用于主要组织相容性复合体I类呈递的蛋白酶体后抗原加工。
Nat Immunol. 2004 Jul;5(7):670-7. doi: 10.1038/ni1089.

加工位点在HLA - A2.1限制性、T细胞反应性肿瘤抗原表位和病毒表位的产生过程中有所不同。

Processing sites are different in the generation of HLA-A2.1-restricted, T cell reactive tumor antigen epitopes and viral epitopes.

作者信息

Yang X F, Mirkovic D, Zhang S, Zhang Q E, Yan Y, Xiong Z, Yang F, Chen I H, Li L, Wang H

机构信息

Department of Pharmacology, Temple University School of Medicine, Philadelphia, USA.

出版信息

Int J Immunopathol Pharmacol. 2006 Oct-Dec;19(4):853-70. doi: 10.1177/039463200601900415.

DOI:10.1177/039463200601900415
PMID:17166407
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2888035/
Abstract

In order to improve the processing efficiency of T cell tumor antigen epitopes, this bioinformatic study compares proteolytic sites in the generation of 47 experimentally identified HLA-A2.1-restricted immunodominant tumor antigen epitopes to those of 52 documented HLA-A2.1-restricted immunodominant viral antigen epitopes. Our results show that the amino acid frequencies in the C-terminal cleavage sites of the tumor antigen epitopes, as well as several positions within the 10 amino acid (aa) flanking regions, are significantly different from those of the viral antigen epitopes. In the 9 amino acid epitope region, frequencies differed somewhat in the secondary-anchored amino acid residues on E3 (the third aa of the epitope), E4, E6, E7 and E8; however, frequencies in the primary-anchored positions, on E2 and E9, for binding in the HLA-A2.1 groove, remained almost identical. The most frequently occurring amino acid pairs in both N-terminal and C-terminal cleavage sites in the generation of tumor antigen epitopes were different from those of the viral antigen epitopes. Our findings demonstrate for the first time that these two groups of epitopes may be cleaved by distinct sets of proteasomes and peptidases or similar enzymes with lower efficiencies for tumor epitopes. In the future, in order to more effectively generate tumor antigen epitopes, targeted activation of the immunoproteasomes and peptidases that mediate the cleavage of viral epitopes could be achieved, thus enhancing our potential for antigen-specific tumor immunotherapy.

摘要

为提高T细胞肿瘤抗原表位的处理效率,这项生物信息学研究将47个经实验鉴定的HLA - A2.1限制性免疫显性肿瘤抗原表位生成过程中的蛋白水解位点与52个已记录的HLA - A2.1限制性免疫显性病毒抗原表位的蛋白水解位点进行了比较。我们的结果表明,肿瘤抗原表位C末端切割位点的氨基酸频率,以及10个氨基酸侧翼区域内的几个位置,与病毒抗原表位的氨基酸频率有显著差异。在9个氨基酸的表位区域,E3(表位的第三个氨基酸)、E4,、E6、E7和E8上的二级锚定氨基酸残基频率略有不同;然而,在HLA - A2.1凹槽中结合的E2和E9上的一级锚定位点的频率几乎保持相同。肿瘤抗原表位生成过程中N末端和C末端切割位点最常出现的氨基酸对与病毒抗原表位的不同。我们的研究结果首次证明,这两组表位可能由不同的蛋白酶体和肽酶或对肿瘤表位效率较低的类似酶切割。未来,为了更有效地生成肿瘤抗原表位,可以实现对介导病毒表位切割的免疫蛋白酶体和肽酶的靶向激活,从而增强我们进行抗原特异性肿瘤免疫治疗的潜力。